multiple sclerosis
279 Results
고급 검색
-
-
Neuroscience Multiplex Assays Using Luminex® Technology | Life Science Research | Merck
Our neuroscience multiplex assays reveal the roles of biomarkers in normal and disease states, in the study of neurological disorders like Parkinson's and ALS. -
Neurodegenerative Diseases | Life Science Research | Merck
Neurodegenerative diseases are characterized by deterioration of neurons or their myelin sheath, disrupting transmission of sensory information, movement control, and more. -
Histones and Histone Modifications | Life Science Research | Merck
Histone modifications regulate DNA transcription, repair, recombination, and replication, and can alter local chromatin architecture. Understanding histone modifications is key to uncovering epigenetic mechanisms of gene regulation. Merck grasps the complexity of this research and provides a growing line of kits, antibodies, and assays for studying histones and their modifications. Merck offers over 600 validated antibodies, recombinant proteins, and kits to analyze histone and histone-variant phosphorylation, methylation, acetylation, ubiquitination, and citrullination-the most widely studied histone modifications in epigenetics today. -
Press Release: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius® Bioreactors
Merck today announced that BioInvent International AB, a Swedish company which develops novel immuno-regulatory antibodies to treat cancer, is upgrading and expanding its drug manufacturing facility with a full line of Merck's Mobius® single-use bioreactors. -
Press Release: Merck Publishes White Paper Highlighting Importance of Emerging Biotech Companies for Discovery of New Drugs During Recent Emerging Biotech Executive Summit
Merck today announced that it has published an original white paper, recognizing the impact the emerging biotech community has on the future of healthcare. -
Press Release: Merck to Provide Provantage® End-to-End Services to Acticor Biotech SAS
Merck today announced that it will provide its Provantage® End-to-End services to Acticor Biotech SAS for accelerated development and manufacturing of Acticor's antibody fragment used for the primary treatment of ischemic stroke. -
Press Release: Merck KGaA to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry
Merck KGaA, Darmstadt Germany, announces that they have entered into a definitive agreement under which Merck KGaA, will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry. -
Press Release: Merck's New Steritest™ Symbio Pump Accessories Enable Faster, Safer Sterility Testing in Any Setting
Merck has introduced a set of Steritest™ Symbio Pump systems accessories that accelerate and streamline sterility testing workflows. -
Press Release: Merck Donates to American Red Cross to Support Greater St. Louis Flood Victims
Merck today announced it has donated $10,000 to the American Red Cross of the Greater St. Louis Region in support of the organization's flood relief efforts.